OBGYN
O-889
O-889 is a synthetic compound that acts as a potent and selective antagonist of the cannabinoid receptor CB1. It is primarily used in scientific research to study the endocannabinoid system and its role in various physiological processes.
Chemical Structure and Properties[edit | edit source]
O-889 is chemically classified as a diarylpyrazole. Its molecular formula is C22H20N4O, and it has a molecular weight of 356.42 g/mol. The compound is characterized by its high affinity for the CB1 receptor, with a Ki value in the low nanomolar range, indicating its potency as an antagonist.
Mechanism of Action[edit | edit source]
O-889 functions by binding to the CB1 receptor, which is a G protein-coupled receptor predominantly found in the central nervous system. By blocking the action of endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol, O-889 inhibits the downstream signaling pathways that are typically activated by these ligands. This blockade can affect various physiological processes, including pain perception, appetite regulation, and mood.
Research Applications[edit | edit source]
O-889 is utilized in preclinical studies to explore the role of the CB1 receptor in different biological systems. It has been instrumental in:
- Pain Research: By antagonizing CB1 receptors, O-889 helps in understanding the modulation of pain pathways and the potential therapeutic applications of CB1 antagonists in pain management.
- Appetite and Metabolism: Studies using O-889 have provided insights into the regulation of appetite and energy balance, contributing to research on obesity and metabolic disorders.
- Neuropsychiatric Disorders: The compound is used to investigate the involvement of the endocannabinoid system in conditions such as anxiety, depression, and schizophrenia.
Safety and Toxicology[edit | edit source]
As with many research chemicals, the safety profile of O-889 is not fully established. It is primarily used in controlled laboratory settings, and its effects in humans are not well-documented. Researchers handling O-889 must adhere to safety protocols to minimize exposure and potential risks.
Also see[edit | edit source]
- Cannabinoid receptor type 1
- Endocannabinoid system
- CB1 receptor antagonists
- Anandamide
- 2-Arachidonoylglycerol
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
